Techniclone (TCLN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EZLibra who wrote (748)	11/21/1997 11:06:00 AM
From: Dave Belz	Read Replies (2) of 3702

Davis I have a couple of questions. For clarity purposes, is the article out of Bethseda about our VTA technology. I know we are cytotoxic and that sets us apart from the other technologies (cytostatic)but some of the new people here may not understand the difference and why we are more valuable with cytotoxic agents. Could you elaborate a little on it. Second, with what products are we to be post surgery v pre surgery? TNT and Glioma cancer is being studied in Atlanta for post surgery as I understand it. Third, when you say licensing for Lym I are you talking about us licensing out to someone other than Alpha? Who will have distribution rights? Lastly, does anyone have any idea why we do not mention more about our Ph II 56% response rate and why that is significant for approval under the new FDA guidelins? It seems that CLTR and IDEC have used their clinical data to generate analyst support and overall impression on the validity of their products. Why dont we do the same?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next